170 related articles for article (PubMed ID: 26853835)
1. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
[TBL] [Abstract][Full Text] [Related]
2. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
[TBL] [Abstract][Full Text] [Related]
3. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
4. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
Dziadek S; Hobel A; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
[No Abstract] [Full Text] [Related]
5. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
[TBL] [Abstract][Full Text] [Related]
6. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
7. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
9. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.
Cai H; Chen MS; Sun ZY; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2013 Jun; 52(23):6106-10. PubMed ID: 23616304
[TBL] [Abstract][Full Text] [Related]
10. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
11. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.
Glaffig M; Palitzsch B; Hartmann S; Schüll C; Nuhn L; Gerlitzki B; Schmitt E; Frey H; Kunz H
Chemistry; 2014 Apr; 20(15):4232-6. PubMed ID: 24623572
[TBL] [Abstract][Full Text] [Related]
12. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
13. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response.
Westerlind U; Hobel A; Gaidzik N; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2008; 47(39):7551-6. PubMed ID: 18704911
[No Abstract] [Full Text] [Related]
14. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
[TBL] [Abstract][Full Text] [Related]
16. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.
Glaffig M; Palitzsch B; Stergiou N; Schüll C; Strassburger D; Schmitt E; Frey H; Kunz H
Org Biomol Chem; 2015 Oct; 13(40):10150-4. PubMed ID: 26299280
[TBL] [Abstract][Full Text] [Related]
17. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of tumor-associated MUC1-glycopeptides and their multivalent presentation by functionalized gold colloids.
Tavernaro I; Hartmann S; Sommer L; Hausmann H; Rohner C; Ruehl M; Hoffmann-Roeder A; Schlecht S
Org Biomol Chem; 2015 Jan; 13(1):81-97. PubMed ID: 25212389
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
20. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
